ReIGNITE is a biotechnology company using Directed Evolution to develop high-capacity viral vectors to unlock the full potential of genetic medicine. ReIGNITE’s complimentary dual viral vector platforms are engineered for the targeted in vivo delivery of oncolytic immunotherapies and gene therapies. Our unique platform leverages the Nobel Prize-winning technologies of Directed Evolution to develop customized high-capacity vectors with tissue-specific tropism.